INTRODUCTION {#s1}
============

In cancer, many cellular processes such as differentiation, growth, migration and survival, are regulated by GTPases of the RAS family. Amongst them K-ras plays a pivotal role in oncogenesis due to its capability of transforming human cells into malignant tumor cells particularly when harboring an activating mutation in codon 12 or 13. *KRAS* mutations frequently occur in many types of human tumors, for example 70 -- 90% in pancreas, 30 -- 60% in colon and 15 -- 50% in lung, making *KRAS* one of the most prominent oncogenes \[[@R1], [@R2]\]. Furthermore, activating oncogenic *KRAS* mutations are often associated with resistance to chemotherapy and targeted therapies \[[@R2]-[@R6]\]. Due to the poor prognosis for cancer patients with mutated *KRAS*, much effort has been spent on developing specific therapies for targeting oncogenic *KRAS*. However, apart from specific RNAi methods, up to now there are no small molecules available which can specifically target K-ras.

miRNAs are endogenous regulators of *KRAS* and many other cellular pathways. Their differential expression in various cancerous tissues compared to normal tissues influences tumorigenesis \[[@R7]\], turning them either into tumor suppressors or oncomirs \[[@R8], [@R9]\]. It has been shown that the let-7 family inhibits *KRAS* \[[@R10]\] resulting in slower proliferation and tumor growth of lung cancer cells \[[@R11]-[@R13]\]. Moreover, miR-143 has been demonstrated to regulate tumorigenesis in colorectal and prostate cancer cells by targeting *KRAS* \[[@R14], [@R15]\]. In pancreatic carcinogenesis it has been reported that the oncogene *EVI1* leads to the activation of the *KRAS* pathway through suppression of the *KRAS* suppressor miR-96 \[[@R16]\]. A recent study has revealed that miR-30c targets the *KRAS* oncogene as well and is deregulated in hereditary breast cancer \[[@R17]\]. In contrast to these tumor suppressor miRNAs, which generally display a low expression level in cancer cells, miR-200c is differentially expressed among cancer cells and acts as important molecular switch by modulating a multitude of cellular processes. miR-200c regulates epithelial-mesenchymal transition (EMT) by inhibiting *ZEB1* and *ZEB2*, the transcriptional repressors of the epithelial marker E-cadherin \[[@R18]-[@R20]\]. By the inhibition of EMT and the regulation of several other genes important for cell motility, miR-200c reduces the migration and invasion of cancer cells, preventing tumor dissemination and metastases \[[@R21]-[@R25]\]. It has also been shown that miR-200c links breast cancer stem cells with normal stem cells and that downregulation of miR-200 is required for the formation and maintenance of cancer stem cells \[[@R26], [@R27]\]. Moreover, in resistant cancer cells miR-200c is able to restore sensitivity to anti-EGFR therapy \[[@R28], [@R29]\] and to classical chemotherapeutics such as paclitaxel or doxorubicin \[[@R30]-[@R33]\]. Therefore, miR-200c targeting *KRAS* is of great interest in order to understand and predict tumor progression and therapy susceptibility of cancer patients.

Here, we report that *KRAS* is targeted by miR-200c, which results in a slower proliferation and in an altered cell cycle of cancer cells. The alterations are dependent on the presence of *KRAS* mutations and occur in different types of cancer.

RESULTS {#s2}
=======

*KRAS* is a predicted target of miR-200c and its protein expression inversely correlates with miR-200c expression in breast cancer cells {#s2_1}
----------------------------------------------------------------------------------------------------------------------------------------

In order to examine whether miR-200c has a putative target site in the 3\'UTR of the *KRAS* gene, online prediction tools were utilized, which were based on the three different algorithms TargetScan \[[@R34]\], miRanda \[[@R35]\] and DIANA microT \[[@R36], [@R37]\]. All applied algorithms uniformly predicted one specific binding site, which is broadly conserved among several species. This predicted site is located at position 305 -- 311 of the *KRAS* 3\'UTR and comprises a 7mer-m8 seed, i.e. a perfect base pairing between the nucleotides 2 -- 7 (seed region) and the nucleotide 8 of the mature miRNA and its target mRNA (Figure [1A](#F1){ref-type="fig"}). As miR-200c is well established and known to be differentially expressed in breast tumors, miR-200c (Figure [1B](#F1){ref-type="fig"}) and K-ras protein (Figure [1C](#F1){ref-type="fig"}) expression levels were analyzed in a panel of different breast cancer cell lines (a numerical table is given in Table [1](#T1){ref-type="table"}). The expression of miR-200c was found to inversely correlate with the K-ras protein expression (Figure [1D](#F1){ref-type="fig"}); i.e. breast cancer cells, which displayed a high miR-200c expression, had low protein levels of K-ras (Pearson r = -0.80). A typical characteristic of advanced cancer is acquired chemoresistance. Since miR-200c as well as particularly mutated K-ras have both been implicated in resistance to classical chemotherapy and targeted therapies \[[@R4], [@R5], [@R28]-[@R33]\], we investigated whether a reduction of miR-200c increases K-ras protein expression in an assay for induced chemoresistance \[[@R32]\]. The miR-200c-positive breast cancer cell line BT-474 was treated with doxorubicin for three rounds, which resulted in reduced miR-200c (Figure [1E](#F1){ref-type="fig"}) and elevated K-ras protein levels (Figure [1F](#F1){ref-type="fig"}) suggesting a miR-200c-dependent regulation of *KRAS*.

![*KRAS* is a predicted target of miR-200c and its protein expression inversely correlates with miR-200c expression in breast cancer cells\
A) Target site prediction of miR-200c in the 3\'UTR of the *KRAS* gene. By means of the three different prediction algorithms TargetScan, miRanda and DIANA microT, a unique conserved binding site with a 7mer-m8 seed at position 305 -- 311 of the 3\'UTR of the *KRAS* gene was found. B) miR-200c expression in a panel of breast cancer cell lines. miR-200c expression was normalized to miR-191 and values are stated as mean ± SD (n=3). C) K-ras protein expression in a panel of breast cancer cell lines. Total cell lysates were subjected to Western blot analysis and incubated with indicated antibodies. D) Correlation of K-ras protein and miR-200c expression. The values of the relative K-ras protein and miR-200c expression are listed in Table [1](#T1){ref-type="table"}. The graph shows the Pearson correlation scatter plot of the relative K-ras and miR-200c levels in the different breast cancer cell lines (\*p\<0.05). Chemotherapeutic treatment of the miR-200c^high^ cell line BT-474. Cells were sequentially treated with 50nM doxorubicin. After each cycle cells were harvested for RNA isolation and protein lysates to determine E) the relative miR-200c expression and F) the K-ras protein levels of the indicated round. Values are stated as mean ± SD (n=3). For statistical analysis a student\'s t-test was performed (\*\*p\<0.01; R0 compared to R3).](oncotarget-05-0185-f001){#F1}

###### Relative miR-200c and K-ras protein expression in the panel of breast cancer cell lines

  Cell line    Relative miR-200c expression \[fold\]   Relative K-ras protein expression \[ratio\]
  ------------ --------------------------------------- ---------------------------------------------
  MDA-MB-157   0.001                                   0.27
  MDA-MB-436   0.001                                   0.70
  MDA-MB-231   0.002                                   0.32
  MDA-MB-435   0.000                                   0.76
  MDA-MB-453   0.142                                   0.54
  MDA-MB-468   0.850                                   0.00
  MCF-7        0.597                                   0.10
  BT-474       1.000                                   0.04

The values of the relative miR-200c expression from Figure [1B](#F1){ref-type="fig"} were stated as fold expression of BT-474 cells. The relative intensities of the Western blot from Figure [1C](#F1){ref-type="fig"} were quantified using ImageJ software. K-ras signals were then normalized to the loading control α-tubulin and depicted as ratio.

miR-200c inhibits K-ras protein expression without affecting *KRAS* mRNA levels {#s2_2}
-------------------------------------------------------------------------------

For the validation of *KRAS* as a novel target of miR-200c, a luciferase reporter assay was performed using a vector encoding for renilla luciferase and almost the entire 3\'UTR of the *KRAS* gene including the predicted miR- 200c binding site. Ectopic expression of this reporter in two miR-200c^low^ (MDA-MB-231 and MDA-MB-436) and two miR-200c^high^ (BT-474 and MCF-7) breast cancer cell lines showed high and low luciferase activities, respectively (Figure [2A](#F2){ref-type="fig"}). This correlation indicates a direct inhibition of the luciferase reporter via the *KRAS* 3\'UTR by miR-200c. Next, it was examined whether miR-200c was able to regulate the luciferase reporter when overexpressed or inhibited. The luciferase reporter was therefore transfected together with pre-miR-200c in MDA-MB-436 cells or miR-200c inhibitor in BT-474 cells. As expected, overexpression of miR-200c led to a decreased luciferase activity, whereas its inhibition resulted in an enhanced bioluminescence (Figure [2B](#F2){ref-type="fig"}). To further prove the inhibition of *KRAS* expression by miR-200c, protein and mRNA levels were determined after either miR-200c inhibition or overexpression. Inhibition of miR-200c in BT-474 and MCF-7 cells led to an elevated K-ras protein expression, while *KRAS* mRNA levels were not changed (Figure [2C](#F2){ref-type="fig"}). On the other hand, overexpression of miR-200c resulted in decreased K-ras protein and unaltered *KRAS* mRNA levels in MDA-MB-231 and MDA-MB-436 cells (Figure [2D](#F2){ref-type="fig"}). Moreover, in the murine breast cancer cell line 4T1, which endogenously displayed a medium expression of miR-200c ([Supplement Figure S1](#SD1){ref-type="supplementary-material"}), it was demonstrated that K-ras protein levels were both down-and up-regulated after miR-200c overexpression and inhibition ([Supplement Figure S2](#SD1){ref-type="supplementary-material"}). In order to assess the silencing efficiency and the mechanism of the miR-200c-induced *KRAS* knockdown, the effects of miR-200c were compared with those of a siRNA-pool against *KRAS* (siRas). While the siRNA knockdown was similar on protein level, siRas remarkably reduced *KRAS* mRNA (Figure [2E](#F2){ref-type="fig"}), consistent with the different modes of action of miRNA- and siRNA-induced gene silencing. Although it has been reported that miRNAs can also down-regulate target mRNAs by affecting their stabilities \[[@R38]\], miR-200c primarily inhibits the translation of *KRAS*, whereas siRas causes the expected mRNA cleavage.

![miR-200c inhibits K-ras protein expression without affecting *KRAS* mRNA levels\
A) Luciferase reporter assay with different breast cancer cell lines. The renilla luciferase reporter containing the 3\'UTR of *KRAS* including the predicted target site of miR-200c (RLuc) or the firefy luciferase control plasmid pGL3 (FLuc) were transfected into the indicated cell lines. Renilla reporter luciferase activity was normalized to the activity of the firefy control as ratio (RLuc/FLuc). Values are stated as mean ± SEM (n=5). B) Luciferase reporter assay upon miR-200c modulation. MDA-MB-436 cells were transfected with either pre-miR-200c (pre) or scrambled pre-miR-control (ctr). BT-474 cells were transfected with either miR-200c inhibitor (inh) or scrambled control inhibitor (ctr). Relative luciferase activities (RLuc/FLuc) are depicted in the graph. Values are stated as mean ± SEM (n=5). For statistical analysis a student\'s t-test was performed (\*\*p\<0.01; \*\*\*p\<0.001). C) miR-200c inhibition in the miR-200c^high^ cell lines BT-474 and MCF-7. Indicated cell lines were transfected with either miR-200c inhibitor (inh) or scrambled control inhibitor (ctr) and at 72h post transfection subjected to Western blot analysis (upper panel) or quantitative RT-PCR (lower panel). Values are stated as mean ± SD (n=3). D) miR-200c overexpression in the miR-200c^low^ cell lines MDA-MB-231 and MDA-MB-436. Indicated cell lines were transfected with either pre-miR-200c (pre) or scrambled pre-miR-control (ctr) and at 72h after transfection subjected to Western blot analysis (upper panel) or quantitative RT-PCR (lower panel). Values are stated as mean ± SD (n=3). E) *KRAS*-specific knockdown in MDA-MB-231 and MDA-MB-436. Cells were transfected either with a siRNA pool against human *KRAS* (siRas) or with a non-targeting control siRNA (siCtr). After 72h K-ras protein (upper panel) and *KRAS* mRNA levels (lower panel) were determined. Values are stated as mean ± SD (n=3). For statistical analysis a student\'s t-test was performed (\*\*p\<0.01; \*\*\*p\<0.001).](oncotarget-05-0185-f002){#F2}

*KRAS* silencing by miR-200c and siRas leads to reduced proliferation and changed cell cycle of breast cancer cells dependent on the *KRAS* mutation status {#s2_3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

The significance of the oncogene *KRAS* is underlined by frequently occurring activating mutations in numerous tumors and cancer cell lines. According to the respective mutation status, different physiological effects were expected upon *KRAS* knockdown. Thus, the cell line MDA-MB-231, which harbors an activating G13D mutation in the *KRAS* gene, and the cell line MDA-MB-436, which expresses the wild-type *KRAS* gene \[[@R39], [@R40]\], were chosen for further experiments. By using pre-miR-200c as well as siRas for the silencing of *KRAS*, the particular role of *KRAS* should be dissected from the role of all the other targets of miR-200c. Several reports have shown that oncogenic K-ras stimulates proliferation in various cell types, highlighting its role in tumorigenesis \[[@R41]-[@R43]\]. Therefore, the proliferation of the two breast cancer cell lines was analyzed upon transfection with pre-miR-200c or siRas. In the *KRAS* mutated cell line MDA-MB-231 the proliferation of pre-miR-200c- and siRas-transfected cells was similarly decreased (Figure [3A](#F3){ref-type="fig"}), whereas in the *KRAS* wild-type cell line MDA-MB-436 only pre-miR-200c was able to significantly reduce proliferation (Figure [3B](#F3){ref-type="fig"}). As it has been demonstrated that oncogenic K-ras drives cell cycle progression by enabling cells to enter the S-phase and thereby promotes tumorigenesis \[[@R44], [@R45]\], cell cycle analyses were additionally performed to investigate whether the cell cycle was differentially affected. Consistent with the proliferation, the cell cycle of MDA-MB-231 cells was considerably changed upon both pre-miR-200c and siRas transfection (Figure [3C](#F3){ref-type="fig"}), whereas only pre-miR-200c changed the cell cycle of MDA-MB-436 cells (Figure [3D](#F3){ref-type="fig"}). Quantification of the cell cycle phases revealed that in MDA-MB-231 cells pre-miR-200c as well as siRas led to a decrease of the G1-phase and an increase of the S-phase (Figure [3E](#F3){ref-type="fig"}). In MDA-MB-436 cells, however, only pre-miR-200c achieved a reduction of the G1-phase and an increase of the S-phase, whereas siRas did not affect the cell cycle (Figure [3F](#F3){ref-type="fig"}).

![*KRAS* silencing by miR-200c and siRas leads to reduced proliferation and changed cell cycle of breast cancer cells dependent on the *KRAS* mutation status\
Proliferation of different breast cancer cell lines upon *KRAS* knockdown. A) MDA-MB-231 cells which harbor an activating (G13D) *KRAS* mutation and B) MDA-MB-436 cells which express wild-type *KRAS* were transfected with pre-miR-200c (pre), scrambled pre-miR-control (ctr), siRNA against *KRAS* (siRas) or non-targeting control siRNA (siCtr). Values are stated as mean cell number ± SD (n=3). For statistical analysis a student\'s t-test was performed (\*\*\*p\<0.001; \*\*\*\*p\<0.0001). Cell cycle of different breast cancer cell lines upon *KRAS* knockdown. C) MDA-MB-231 and D) MDA-MB-436 cells were subjected to flowcytometry at 72h after transfection with the indicated oligonucleotides. Cell cycle analysis was carried out using FlowJo software. Results are presented as histograms (y-axis: counts; x-axis: PE-Texas Red indicative for propidium iodide). Statistical analysis of the cell cycle phases upon *KRAS* silencing. The percentage of E) MDA-MB-231 and F) MDA-MB-436 cells in the respective cell cycle phase upon indicated oligonucleotide transfection was determined. Values are stated as mean ± SD (n=3). For statistical analysis a student\'s t-test was performed (\*\*\*\*p\<0.0001)](oncotarget-05-0185-f003){#F3}

miR-200c and siRas also affect the cell cycle of lung cancer cells by inhibiting *KRAS* {#s2_4}
---------------------------------------------------------------------------------------

As the relevance of *KRAS* mutations in breast cancer remains elusive, the physiological effects of miR-200c-dependent *KRAS* silencing were explored in a more relevant cancer type. Besides in pancreas and colon cancer, *KRAS* mutations occur very frequently in non-small cell lung cancer (NSCLC) (15-50%) \[[@R2], [@R4]\].

Thus, the two NSCLC cell lines A549 and Calu-1 were used, which harbor the activating *KRAS* mutations G12S and G12C, respectively \[[@R46], [@R47]\]. Both lung cancer cell lines displayed low miR-200c levels (Figure [4A](#F4){ref-type="fig"}) but a considerable K-ras protein expression (Figure [4B](#F4){ref-type="fig"}) as compared to the miR-200c^high^ breast cancer cell line BT-474. The cell cycle upon *KRAS* knockdown was determined in the two lung cancer cell lines to examine whether the effects were comparable with those of the *KRAS* mutated breast cancer cell line MDA-MB-231. Of note, the cell cycle of pre-miR-200c- as well as siRas-transfected A549 (Figure [4C](#F4){ref-type="fig"}) and Calu-1 (Figure [4D](#F4){ref-type="fig"}) cells was similarly changed. In accordance with MDA-MB-231 cells, the G1-phase was decreased, whereas the S-phase was increased in A549 (Figure [4E](#F4){ref-type="fig"}) and Calu-1 (Figure [4F](#F4){ref-type="fig"}) cells. These data suggest that miR-200c can generally interfere with cell proliferation and cell cycle by directly targeting oncogenic *KRAS* independent of the respective cancer type. Furthermore, these results highlight the prominent role of the miR-200c-dependent regulation of *KRAS*, especially when applied to cell lines which are driven by oncogenic *KRAS*.

![miR-200c and siRas also affect the cell cycle of lung cancer cells by inhibiting *KRAS*\
A) miR-200c expression and B) K-ras protein levels of the two *KRAS* mutated lung cancer cell lines A549 (G12S) and Calu-1 (G12D) in comparison to the breast cancer cell line BT-474. Values are stated as mean ± SD (n=3). Cell cycle of different lung cancer cell lines upon *KRAS* knockdown. C) A549 cells and D) Calu-1 cells were subjected to flowcytometry at 72h after transfection with pre-miR-200c (pre), scrambled pre-miR-control (ctr), siRNA against *KRAS* (siRas) or non-targeting control siRNA (siCtr). Cell cycle analysis was carried out using FlowJo software. Results are presented as histograms (y-axis: counts; x-axis: PE-Texas Red indicative for propidium iodide). Statistical analysis of the cell cycle phases upon *KRAS* silencing. The percentage of E) A549 and F) Calu-1 cells in the respective cell cycle phase upon indicated oligonucleotide transfection was analyzed. Values are stated as mean ± SD (n=3). For statistical analysis a student\'s t-test was performed (\*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001).](oncotarget-05-0185-f004){#F4}

DISCUSSION {#s3}
==========

Various cellular processes, such as differentiation, proliferation and survival are regulated by the GTPase K-ras. Frequently occurring activating mutations turn *KRAS* into one of the most prominent oncogenes. Similarly, a pivotal role in tumorigenesis as a molecular switch between an epithelial, non-migratory, chemosensitive and a mesenchymal, migratory, chemoresistant state has been attributed to miR-200c. While it has been reported that *KRAS* is regulated by several tumor suppressor miRNAs, this is the first report on the direct regulation of *KRAS* by miR-200c.

Thereby, *KRAS* was experimentally validated as a target of miR-200c by Western blot analyses and luciferase reporter assays. Interestingly, upon molecular evolution, an assay for acquired chemoresistance in which cancer cells were sequentially treated with doxorubicin, BT-474 cells displayed a significantly reduced miR-200c and a remarkably enhanced K-ras protein expression. Even though BT-474 cells express wild-type K-ras \[[@R39]\], the up-regulation of K-ras is a reasonable way to overcome the chemotherapeutic treatment as those cells have an amplification of the pro-survival gene *ERBB2* encoding for the receptor tyrosine kinase Her2 \[[@R48]\], which signals downstream among others via the RAS/MAPK signaling pathway. This suggests that not only the presence of mutated but also the expression levels of wild-type K-ras are important for tumor progression and may serve as predictive marker for therapy efficacy, especially when occurring in combination with other genetic alterations such as *EGFR* mutations or *ERBB2* amplifications.

Furthermore, in different breast and lung cancer cell lines an inhibitory effect of miR-200c-dependent *KRAS* silencing on proliferation and cell cycle was demonstrated. Specific knockdown experiments using siRNA against *KRAS* dissected the particular role of *KRAS* from the role of the other miR-200c targets. miR-200c as well as the siRNA against *KRAS* similarly affected the cell cycle of MDA-MB-231, A549 and Calu-1 cells, which harbor an activating *KRAS* mutation. However, in the *KRAS* wild-type cell line MDA-MB-436 only miR-200c was able to change proliferation and cell cycle. Uhlmann *et al*. \[[@R49]\] have shown that in MDA-MB-231 cells the miR-200bc/429 seed-cluster, in particular miR-200c, inhibits EGF-driven invasion as well as proliferation and cell cycle progression, the latter by decreasing the G1-population. However, they ascribed the physiological effects to a miR-200c-induced down-regulation of PLC gamma 1, regardless of the *KRAS* mutation status. While the effects on invasion were nicely refected by a specific knockdown of PLC gamma 1, the effects on proliferation were only mimicked in part. Here, it was shown that the effects on proliferation and cell cycle are coinciding for miR-200c and siRas if an activating *KRAS* mutation is present. These results indicate that in MDA-MB-231 cells, which harbor the activating *KRAS* mutation G13D, miR-200c inhibits proliferation and cell cycle progression more likely via a down-regulation of *KRAS*. On the contrary, in cells harboring wild-type *KRAS*, only miR-200c is able to alter proliferation and cell cycle presumably via other targets than *KRAS*, for instance *BMI1*. The polycomb group repressor Bmi1 induces transcriptional repression of a variety of genes including p16^Ink4a^ of the Ink4a locus, which causes cell cycle arrest and senescence \[[@R50]\]. Hence, miR-200c shows a broader efficacy than siRas against cancer cells by targeting multiple genes and pathways.

Activating mutations in the *KRAS* gene are important drivers of carcinogenesis in many types of cancer, such as lung, colon and pancreas \[[@R1], [@R2]\]. However, it has been reported that human tumors display a remarkable intratumoral heterogeneity \[[@R51]\], which is furthermore associated with drug resistance and the failure of cancer therapies \[[@R52]\]. Oncogenic K-ras might not necessarily be expressed across an entire tumor, but rather cellular subpopulations may exist which display the wild-type *KRAS* gene. These cell populations can additionally contribute to tumor progression and to an aggressive phenotype including a high propensity of cancer cells to metastasize and to overcome drug treatment. Therefore, usage of miR-200c in a therapeutic approach may be superior to that of a siRNA against *KRAS*. As demonstrated by several reports, this miRNA has multiple targets \[[@R53]\], which regulate crucial events for tumor progression, e.g. epithelial-mesenchymal transition (EMT), acquisition of stem-like properties or therapy resistance (Figure [5](#F5){ref-type="fig"}).

![Regulatory network of miR-200c\
While siRas can only specifically target *KRAS* mRNA, miR-200c regulates a variety of genes involved in tumor progression, metastasis and therapy resistance. By controlling a multitude of cellular processes, miR-200c causes stronger effects against various cancer cells independent of the mutational status of *KRAS*. The targets depicted in the diagram and their respective biological roles are reviewed in \[[@R53]\].](oncotarget-05-0185-f005){#F5}

Moreover, KEGG-pathway analysis of all potential miR-200c targets predicted by TargetScan \[[@R34]\] revealed that miR-200c might strongly interact with the MAPK and ERBB signaling pathway by regulating a multitude of target genes, such as central adaptor proteins like Shc and Sos, kinases like *MEKK1* and *PKC* or transcription factors like *SRF* and *JUN* ([Supplement Figure S3](#SD1){ref-type="supplementary-material"}). Although the direct regulation of these targets needs to be proven, these findings indicate that miR-200c may have additional regulating functions as a kind of gatekeeper of tumor progression and therapy resistance by controlling a complex network of oncogenic pathways including the RAS/MAPK pathway.

METHODS {#s4}
=======

Oligonucleotides {#s4_1}
----------------

The following oligonucleotides were used: miRCURY LNA miRNA Inhibitor for hsa-miR-200c (inh) (Exiqon), miRCURY LNA miRNA Inhibitor Control Negative Control A (ctr) (Exiqon), Pre-miR miRNA Precursor of hsa-miR-200c (pre) (Ambion), Pre-miR miRNA Negative Control (ctr) (Ambion), ON-TARGETplus SMARTpool siRNA against human *KRAS* consisting of four different siRNAs (Dharmacon) (siRas) and the non-targeting control siRNA (siCtr), which was previously described \[[@R54]\].

Cell Culture {#s4_2}
------------

The breast cancer cell lines MDA-MB-157, MDA-MB-436, MDA-MB-231, MDA-MB-435 (formerly regarded as breast cancer, in fact melanoma), MDA-MB-453, MDA-MB-468, MCF-7, BT-474 and 4T1 as well as the lung cancer cell lines A549 and Calu-1 were cultivated according to supplier\'s instructions (ATCC).

Quantitative RT-PCR {#s4_3}
-------------------

Total RNA was isolated followed by a reverse transcription and a quantitative RT-PCR as described previously \[[@R32]\]. Primers and UPL hydrolysis probes (Roche) are listed in [Supplement Table S1](#SD2){ref-type="supplementary-material"}.

Cell Lysis and Immunoblotting {#s4_4}
-----------------------------

Western blot experiments were performed as previously described \[[@R32]\] using the primary antibodies against the following proteins: K-ras (415700, Invitrogen), actin (I-19) (SC-1616, Santa Cruz) and α-tubulin (DM-1A) (T9026, Sigma). Western blots were quantified using ImageJ software \[[@R55]\]. The K-ras intensities were thereby normalized to the intensities of the loading control (actin or α-tubulin) and presented as ratio or fold expression.

Doxorubicin Treatment of BT-474 Cells {#s4_5}
-------------------------------------

BT-474 cells were sequentially treated with 50nM doxorubicin (doxorubicin hydrochloride, Sigma) for 72h as described previously \[[@R32]\]. As soon as the cells recovered (confluence of 80%) the next treatment round was started. After each cycle cells were harvested for RNA isolation and protein lysates.

Oligonucleotide Transfections {#s4_6}
-----------------------------

Indicated cell lines were transfected with the above mentioned oligonucleotides using Lipofectamine 2000 (Invitrogen) according to manufacturer\'s protocol. The following nucleotide amounts were thereby used: in 6-well plates (used for quantitative RT-PCR and Western blot) 75pmol, in 24-well plates (used for cell cycle) 15pmol, in 48-well plates (used for proliferation) 7.5pmol and in 96-well plates (used for luciferase assays) 3pmol.

Luciferase Reporter Assays {#s4_7}
--------------------------

A renilla luciferase reporter plasmid containing the almost entire 3\'UTR of the *KRAS* gene was obtained from Addgene (Addgene plasmid 44571). This plasmid was generated by Frank Slack and is based on the plasmid with the let-7 mutated binding site LCS6m from the publication Chin *et al*. \[[@R56]\]. The renilla luciferase reporter containing the 3\'UTR of *KRAS* (RLuc) or the firefly luciferase control plasmid pGL3 (Promega) (FLuc) were transfected into the indicated cell lines using Lipofectamine 2000 (Invitrogen) according to manufacturer\'s instructions. All RLuc signals were normalized to the respective FLuc signals as ratio (RLuc/FLuc). Additionally, MDA-MB-436 cells were transfected with either pre-miR-200c (pre) or pre-miR-control (ctr) (Ambion) together with the reporter plasmid RLuc and the control plasmid FLuc for normalization. BT-474 cells were transfected with either the LNA miR-200c inhibitor (inh) or the LNA control inhibitor (ctr) (Exiqon) together with the reporter plasmid RLuc and the control plasmid FLuc for normalization. All luciferase assays were performed in 96-well plates at 48h post transfection.

Proliferation Assay {#s4_8}
-------------------

To examine proliferation, cells were seeded in 48-well plates. The following day, cells were transfected with indicated oligonucleotides and starting with day one after transfection proliferation was measured over seven days at indicated time points using a Scepter cell counter (Millipore).

Cell Cycle Analysis {#s4_9}
-------------------

For the acquisition of the cell cycle, cells were seeded in 24-well plates and transfected with the indicated oligonucleotides the following day. At 72h after transfection the cells were subjected to flowcytometry. For this purpose, cells were trypsinized, centrifuged and incubated on ice for four hours in propidium iodide staining solution consisting of 0.1% sodium citrate, 0.1% Triton X-100 and 50µg/ml propidium iodide. Thereafter, cells were centrifuged, resuspended in phosphate buffered saline and analyzed with a CyAn ADP flowcytometer (Beckman Coulter). Doublets were discriminated by gating forward versus sideward scatter and forward scatter versus pulse width. The DNA content was measured through excitation of the dye at 488nm and detection of the emission with a 613/20 bandpass filter. Cell cycle analysis was carried out using FlowJo software.
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